Market Cap 52.35M
Revenue (ttm) 11.20M
Net Income (ttm) 10,000.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.09%
Debt to Equity Ratio 0.00
Volume 267,100
Avg Vol 153,050
Day's Range N/A - N/A
Shares Out 5.55M
Stochastic %K 49%
Beta 0.99
Analysts Sell
Price Target $10.88

Company Profile

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone...

Industry: Biotechnology
Sector: Healthcare
Phone: 801 994 7383
Fax: 801 994 7388
Address:
675 Arapeen Drive, Suite 202, Salt Lake City, United States
mattyGLTATTFNBFOT
mattyGLTATTFNBFOT Feb. 26 at 11:33 PM
$LPCN Under the Prior Prospectus, we registered up to an aggregate of $10,616,169 of our common stock, $0.0001 par value per share, for offer and sale pursuant to a sales agreement, dated April 26, 2024, (the “Sales Agreement”), between us and A.G.P./Alliance Global Partners. From April 26, 2024 through the date of this prospectus supplement, we sold an aggregate of 1,603,431 shares of our common stock, for an aggregate purchase price of $10,615,576 under the Prior Prospectus. As of the date of this prospectus supplement, we are increasing the aggregate amount of common stock that we are offering pursuant to the Sales Agreement, such that we are offering up to an aggregate of $50,000,000 of our common stock for sale under the Sales Agreement, including the shares of common stock previously sold, or $39,384,424 from and after the date hereof.
1 · Reply
Ma_pooperz
Ma_pooperz Feb. 26 at 9:38 PM
$LPCN Reality starting to set in people cant deny this stock about to fly
0 · Reply
ITF
ITF Feb. 26 at 7:22 PM
$LPCN lovin' the volume this week, winding that spring before letting it rip
0 · Reply
DivvyDoo
DivvyDoo Feb. 24 at 8:31 PM
$LPCN almost 200k volume today
1 · Reply
amazingcrwns
amazingcrwns Feb. 24 at 6:14 PM
$LPCN Clinical Trials update. Status: Completed. https://clinicaltrials.gov/study/NCT06979544?term=Lipocine&rank=1
2 · Reply
mattyGLTATTFNBFOT
mattyGLTATTFNBFOT Feb. 24 at 5:01 PM
$LPCN Discounting the last few months, who thinks we get a run up to April results? I think we do based on past performance. We’ll see.
1 · Reply
Ma_pooperz
Ma_pooperz Feb. 23 at 7:51 PM
$LPCN Strong volume today looking back up
0 · Reply
Ma_pooperz
Ma_pooperz Feb. 23 at 6:12 PM
$LPCN why people gotta hate 10
0 · Reply
HITbidsHARD
HITbidsHARD Feb. 23 at 2:41 PM
2 · Reply
Ma_pooperz
Ma_pooperz Feb. 23 at 5:24 AM
$LPCN The only thing to be depressed about after topline results is you didn't buy more, much less post partum
0 · Reply
Latest News on LPCN
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

Nov 4, 2025, 8:00 AM EST - 4 months ago

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®


Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

May 14, 2025, 8:00 AM EDT - 10 months ago

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase


Lipocine Receives Updated Regulatory Guidance on LPCN 1154

Feb 6, 2025, 8:00 AM EST - 1 year ago

Lipocine Receives Updated Regulatory Guidance on LPCN 1154


Lipocine to Present at 36th Annual Roth Conference

Mar 6, 2024, 8:00 AM EST - 2 years ago

Lipocine to Present at 36th Annual Roth Conference


Lipocine to Present at Biotech Showcase 2024

Dec 19, 2023, 8:00 AM EST - 2 years ago

Lipocine to Present at Biotech Showcase 2024


mattyGLTATTFNBFOT
mattyGLTATTFNBFOT Feb. 26 at 11:33 PM
$LPCN Under the Prior Prospectus, we registered up to an aggregate of $10,616,169 of our common stock, $0.0001 par value per share, for offer and sale pursuant to a sales agreement, dated April 26, 2024, (the “Sales Agreement”), between us and A.G.P./Alliance Global Partners. From April 26, 2024 through the date of this prospectus supplement, we sold an aggregate of 1,603,431 shares of our common stock, for an aggregate purchase price of $10,615,576 under the Prior Prospectus. As of the date of this prospectus supplement, we are increasing the aggregate amount of common stock that we are offering pursuant to the Sales Agreement, such that we are offering up to an aggregate of $50,000,000 of our common stock for sale under the Sales Agreement, including the shares of common stock previously sold, or $39,384,424 from and after the date hereof.
1 · Reply
Ma_pooperz
Ma_pooperz Feb. 26 at 9:38 PM
$LPCN Reality starting to set in people cant deny this stock about to fly
0 · Reply
ITF
ITF Feb. 26 at 7:22 PM
$LPCN lovin' the volume this week, winding that spring before letting it rip
0 · Reply
DivvyDoo
DivvyDoo Feb. 24 at 8:31 PM
$LPCN almost 200k volume today
1 · Reply
amazingcrwns
amazingcrwns Feb. 24 at 6:14 PM
$LPCN Clinical Trials update. Status: Completed. https://clinicaltrials.gov/study/NCT06979544?term=Lipocine&rank=1
2 · Reply
mattyGLTATTFNBFOT
mattyGLTATTFNBFOT Feb. 24 at 5:01 PM
$LPCN Discounting the last few months, who thinks we get a run up to April results? I think we do based on past performance. We’ll see.
1 · Reply
Ma_pooperz
Ma_pooperz Feb. 23 at 7:51 PM
$LPCN Strong volume today looking back up
0 · Reply
Ma_pooperz
Ma_pooperz Feb. 23 at 6:12 PM
$LPCN why people gotta hate 10
0 · Reply
HITbidsHARD
HITbidsHARD Feb. 23 at 2:41 PM
2 · Reply
Ma_pooperz
Ma_pooperz Feb. 23 at 5:24 AM
$LPCN The only thing to be depressed about after topline results is you didn't buy more, much less post partum
0 · Reply
Tothemoonemoji
Tothemoonemoji Feb. 20 at 9:56 PM
$LPCN nice volume change from yesterday
0 · Reply
veseli
veseli Feb. 20 at 12:56 AM
0 · Reply
Ma_pooperz
Ma_pooperz Feb. 19 at 6:20 PM
$LPCN 3k volume today whats going on
2 · Reply
brunoq14
brunoq14 Feb. 19 at 12:28 PM
$LPCN When did they add LPCN2201 for MDD? I missed that one.
2 · Reply
PaytiencePaysGreen
PaytiencePaysGreen Feb. 19 at 11:05 AM
$LPCN so, is it going to be Apr or end Mar?
3 · Reply
JackLewisLPCN
JackLewisLPCN Feb. 18 at 9:22 PM
$LPCN if a run up is going to start before phase 3, it feels like now should be the time. This is one of the few times that it's not a "sell the news" situation. What are the expectations of stock price in the weeks months after topline if both efficacy and safety are similar to brexanolone? That should mean 1154 takes brex's and zuranolone's entire market share in the next 2-3 years. Maybe edges into some SSRI territory (but honestly not much). I don't see how meeting brex's safety/efficacy (or close to) doesn't push lpcn to around 40-50 at a minimum. Am I wrong?
3 · Reply
amazingcrwns
amazingcrwns Feb. 18 at 7:10 PM
$LPCN With the PR about LPLV, I didn't even notice that they also updated the corporate presentation this morning. Kind of surprised to get it now instead of in March just before the annual report comes out. I just had time to skim it, nice new slide on 1154 safety, anybody else see anything interesting?
1 · Reply
Ma_pooperz
Ma_pooperz Feb. 18 at 4:50 PM
$LPCN We are going back up by end of day mark it
0 · Reply
az2001
az2001 Feb. 18 at 4:29 PM
$LPCN Honestly for me the main concern was the safety profile, and based on Patels statements we have hit that mark. I am not that concerned about efficacy because we have established bioequivalency to Zulresso. The main concern coming out of this topline data for me was are we meeting those safety goals and it looks like we have at worst a similar safety profile to Zurzuvae while having a much more convenient and prompt delivery system.
2 · Reply
amazingcrwns
amazingcrwns Feb. 18 at 4:13 PM
$LPCN Follow-up to my earlier post about projecting topline data. I went back and checked the timeline from the Sage trial for IV brexanolone that this trial closely followed. Sage's primary completion date was September 24th, 2017, and the primary endpoint press release was November 9th, 46 days later. My understanding is Lipocine's primary completion date for this trial would have been between Jan 15th and 21st, depending on when exactly that last patient was dosed before the complete enrollment press release came out on Jan 20th. Sage also had 30 day patient monitoring secondary endpoints. There are a lot of variables to the data analysis, clinical sites could need to track down information that delays things, statistical analysis teams don't all operate at the same speed, there could be backlogs, etc. I guess my point is, after looking at the Sage timeline, I won't be surprised if we get news sooner than I was expecting.
3 · Reply
az2001
az2001 Feb. 18 at 3:36 PM
$LPCN Buy this up while you still can
0 · Reply
BioTuesdays
BioTuesdays Feb. 18 at 3:00 PM
$LPCN has announced that the last patient has completed the final study visit in the Phase 3 trial of its oral brexanolon, LPCN 1154, for the treatment of postpartum depression (PPD). https://biotuesdays.com/2026/02/18/lipocine-completes-phase-3-trial-of-lpcn-1154-in-ppd/
0 · Reply